Literature DB >> 16326921

S-adenosyl-L-homocysteine hydrolase inactivation curtails ovalbumin-induced immune responses.

Yun-Feng Fu1, Jun-Xia Wang, Yang Zhao, Yang Yang, Wei Tang, Jia Ni, Yi-Na Zhu, Ru Zhou, Pei-Lan He, Chuan Li, Xiao-Yu Li, Yi-Fu Yang, Brian R Lawson, Jian-Ping Zuo.   

Abstract

The reversible S-adenosyl-L-homocysteine (AdoHcy) hydrolase inhibitor methyl 4-(adenin-9-yl)-2-hydroxybutanoate (DZ2002) suppresses macrophage activation and function. The effects of DZ2002 on T cell function, however, are still unclear. Here, we examined whether DZ2002 alters type 1 helper T cell (Th1) and/or type 2 helper T cell (Th2) immune responses, and whether these effects are associated with both the inhibition of AdoHcy hydrolase and intracellular elevation of endogenous AdoHcy. Male C57BL/6 mice immunized with ovalbumin (OVA) were treated with DZ2002 (1, 5, and 25 mg/kg/day) after which lymphocyte proliferation, cytokine production, and IgG responses to OVA were monitored. Administration of DZ2002 dose dependently suppressed OVA-specific lymphocyte proliferation and anti-OVA IgG production compared with controls. Interleukin (IL)-2 and interferon (IFN)-gamma as well as anti-OVA IgG2a and IgG3, indicators of Th1 immune responses, were markedly decreased in mice treated with DZ2002, whereas IL-4 and anti-OVA IgG1, indicators of Th2 immune responses, were only mildly suppressed. AdoHcy hydrolase activity in spleens of DZ2002-treated mice was substantially blocked, and not surprisingly, AdoHcy levels were significantly elevated compared with controls. Finally, similar immunosuppressive effects were also observed in mice treated with AdoHcy. These data strongly indicate that DZ2002 suppresses antigen-induced specific immune responses, particularly Th1 responses, through inhibition of AdoHcy hydrolase and elevation of endogenous AdoHcy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16326921     DOI: 10.1124/jpet.105.093369

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  An endogenously anti-inflammatory role for methylation in mucosal inflammation identified through metabolite profiling.

Authors:  Douglas J Kominsky; Simon Keely; Christopher F MacManus; Louise E Glover; Melanie Scully; Colm B Collins; Brittelle E Bowers; Eric L Campbell; Sean P Colgan
Journal:  J Immunol       Date:  2011-04-22       Impact factor: 5.422

Review 2.  Transmethylation in immunity and autoimmunity.

Authors:  Brian R Lawson; Theodoros Eleftheriadis; Virginie Tardif; Rosana Gonzalez-Quintial; Roberto Baccala; Dwight H Kono; Argyrios N Theofilopoulos
Journal:  Clin Immunol       Date:  2011-12-24       Impact factor: 3.969

3.  Lupus autoimmunity altered by cellular methylation metabolism.

Authors:  Mei-Ling Yang; Alaric J P Gee; Renelle J Gee; Cecilia I Zurita-Lopez; Shilpi Khare; Steven G Clarke; Mark J Mamula
Journal:  Autoimmunity       Date:  2012-11-01       Impact factor: 2.815

4.  Critical role of transmethylation in TLR signaling and systemic lupus erythematosus.

Authors:  Virginie Tardif; Yulia Manenkova; Michael Berger; Kasper Hoebe; Jian-Ping Zuo; Chong Yuan; Dwight H Kono; Argyrios N Theofilopoulos; Brian R Lawson
Journal:  Clin Immunol       Date:  2013-03-05       Impact factor: 3.969

5.  Therapeutic effects of DZ2002, a reversible SAHH inhibitor, on lupus-prone NZB×NZW F1 mice via interference with TLR-mediated APC response.

Authors:  Shi-jun He; Ze-min Lin; Yan-wei Wu; Bing-xin Bai; Xiao-qian Yang; Pei-lan He; Feng-hua Zhu; Wei Tang; Jian-ping Zuo
Journal:  Acta Pharmacol Sin       Date:  2013-12-30       Impact factor: 6.150

6.  IL-27 supports germinal center function by enhancing IL-21 production and the function of T follicular helper cells.

Authors:  Marcel Batten; Nandhini Ramamoorthi; Noelyn M Kljavin; Cindy S Ma; Jennifer H Cox; Hart S Dengler; Dimitry M Danilenko; Patrick Caplazi; Melanie Wong; David A Fulcher; Matthew C Cook; Cecile King; Stuart G Tangye; Frederic J de Sauvage; Nico Ghilardi
Journal:  J Exp Med       Date:  2010-11-22       Impact factor: 14.307

7.  Artemisinin analogue SM934 attenuate collagen-induced arthritis by suppressing T follicular helper cells and T helper 17 cells.

Authors:  Ze-Min Lin; Xiao-Qian Yang; Feng-Hua Zhu; Shi-Jun He; Wei Tang; Jian-Ping Zuo
Journal:  Sci Rep       Date:  2016-11-29       Impact factor: 4.379

8.  Assay development for determination of DZ2002, a new reversible SAHH inhibitor, and its acid metabolite DZA in blood and application to rat pharmacokinetic study.

Authors:  Weiwei Jia; Jing Li; Feifei Du; Yan Sun; Fang Xu; Fengqing Wang; Olajide E Olaleye; Danghui Chen; Wei Tang; Jianping Zuo; Chuan Li
Journal:  J Pharm Anal       Date:  2018-09-07

9.  DZ2002 ameliorates fibrosis, inflammation, and vasculopathy in experimental systemic sclerosis models.

Authors:  Zongwang Zhang; Yanwei Wu; Bing Wu; Qing Qi; Heng Li; Huimin Lu; Chen Fan; Chunlan Feng; Jianping Zuo; Lili Niu; Wei Tang
Journal:  Arthritis Res Ther       Date:  2019-12-16       Impact factor: 5.156

10.  DNA methylation of AHCY may increase the risk of ischemic stroke.

Authors:  Lei Zhao; Xiaosheng Chen; Shengjun Zhou; Zhiqing Lin; Xi Yu; Yi Huang
Journal:  Bosn J Basic Med Sci       Date:  2020-11-02       Impact factor: 3.363

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.